

Please be sure to complete the following:

Company name-----CytoReason----- * Website-----www.cytoreason.com----- *

CEO name-----David Harel-----*

Contact Person: Zeev Ben Shachar – 054-5883181

Speaker at the panel: Yael Villa – CTO at CytoReason – 054-5330233

Highlight the relevant session below -

1. Longevity - How to Complete the Centenarian Decathlon?
2. Do we Know Enough About the Brain to Treat Neurological Disorders?
3. Are Cancer Therapeutics Fulfilling the Promise?
4. Can we Successfully Diagnose and Guide Patients' Optimal Cancer Treatment?
5. **AI Tapestry: Optimizing the Interaction of AI and Biopharma**
6. Facts and Myths on Ex-Liver Drug Delivery and New Horizons to Cure Rare Disorders
7. Who Owns Health Decisions? The Changing Dynamics of Patient-Physician Relationships in the Digital Health Revolution
8. Robots Dancing with Humans in the Healthcare Systems and Homes
9. Are Medical Devices Still Relevant in the Context of New Biology?
10. Let Food be Thy Medicine and Medicine be Thy Food
11. How do we make Academic Translation Medicine replicable and relevant?
12. Bio Convergence: Everything That Rises Must Converge
13. High Pace Innovation in Dermatology & Medical Aesthetics
14. Navigating Global Collaborations in Times of Uncertainty: Can we turn challenges into growth opportunities?
15. Ophthalmology, from R&D to Commercialization

Title of the Presentation:

Managing your drug portfolio with an AI platform and computational disease models

Executive Summary / Investment Rational

Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

CytoReason is a tech company developing computational disease models, with the goal of transforming medicine from trial-and-error to a predictable practice.

With its proprietary database and disease model platform, the company simulates human diseases – tissue by tissue and cell by cell.

To date, five of the world's top ten pharma companies use CytoReason's technology.

In 2022, the CytoReason expanded its partnership with [Pfizer](#) in a \$110m commercial deal, including a \$20m equity investment. And in 2023, the company expanded its collaboration with [Sanofi](#), licensing its IBD disease model in a multiyear, multimillion-dollar deal.

With headquarters in Tel Aviv and branches in the US and Europe, CytoReason was founded in 2016 by renowned Technion Prof. Shai Shen-Orr, and successful healthcare executive David Harel. CytoReason's science and technology breakthroughs have been published in dozens of top-tier journals, such as Nature and Cell. The Company's leadership is highly skilled and experienced in pharma, AI, and machine learning technologies, and over 50% of the Company's employees hold PhDs in relevant fields of science.

Core Technology

What is the technology, its uniqueness, and its value proposition?

CytoReason's disease model technology and professional services enable multiple stakeholders in the organization to make data-driven decisions. Scientists can identify targets and prioritize indications. Managers can conduct synthetic trials – to compare one drug across several diseases, or multiple drugs across one disease. And C-level executives can manage their entire drug portfolio.